Mehta Analysis: Trump Pricing Tempest In A Teapot Is An Opportunity For Biopharma Leaders
Executive Summary
President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.
You may also be interested in...
Trump's Drug Pricing Plan – What The Choice Of Words May Mean For India
The Trump Administration’s blueprint on prescription drugs and reducing out-of-pocket costs may still be a work in progress, but there appears to be a careful choice of words, which some experts in developing nations like India believe are pointers on what to expect.
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.